Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 1/2 3Phase 2 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 2Sarcoma 1Neoplasm, Residual 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × siremadlin × Clear all
NCT05180695 2026-02-10

AMPHISARC

Centre Leon Berard

Phase 1/2 Active not recruiting
47 enrolled
Sarcoma

Sarcoma

NCT05447663 2025-05-16

A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant

Novartis

Phase 1/2 Terminated
8 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Novartis

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡